Transcription factor E2F‐1 acts as a growth‐promoting factor and is associated with adverse prognosis in non‐small cell lung carcinomas
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Numerous upstream stimulatory and inhibitory signals converge to the pRb/E2F pathway, which governs cell‐cycle progression, but the information concerning alterations of E2F‐1 in primary malignancies is very limited. Several in vitro studies report that E2F‐1 can act either as an oncoprotein or as a tumour suppressor protein. In view of this dichotomy in its functions and its critical role in cell cycle control, this study examined the following four aspects of E2F‐1 in a panel of 87 non‐small cell lung carcinomas (NSCLCs), previously analysed for defects in the pRb‐p53‐MDM2 network: firstly, the status of E2F‐1 at the protein, mRNA and DNA levels; secondly, its relationship with the kinetic parameters and genomic instability of the tumours; thirdly, its association with the status of its transcriptional co‐activator CBP, downstream target PCNA and main cell cycle regulatory and E2F‐1‐interacting molecules pRb, p53 and MDM2; and fourthly, its impact on clinical outcome. The protein levels of E2F‐1 and its co‐activator CBP were significantly higher in the tumour area than in the corresponding normal epithelium (p<0.001). E2F‐1 overexpression was associated with increased E2F‐1 mRNA levels in 82% of the cases examined. The latter finding, along with the low frequency of E2F‐1 gene amplification observed (9%), suggests that the main mechanism of E2F‐1 protein overexpression in NSCLCs is deregulation at the transcriptional level. Mutational analysis revealed only one sample with asomatic mutation at codon 371 (Glu→Asp) and one carrying a polymorphism at codon 393 (Gly→Ser). Carcinomas with increased E2F‐1 positivity demonstrated a significant increase in their growth indexes (r=0.402, p=0.001) and were associated with adverse prognosis (p=0.033 by Cox regression analysis). The main determinant of the positive association with growth was the parallel increase between E2F‐1 staining and proliferation (r=0.746, p<0.001), whereas apoptosis was not influenced by the status of E2F‐1. Moreover, correlation with the status of the pRb–p53–MDM2 network showed that the cases with aberrant pRb expression displayed significantly higher E2F‐1 indexes (p=0.033), while a similar association was noticed in the group of carcinomas with deregulation of the p53–MDM2 feedback loop. In conclusion, the results suggest that E2F‐1 overexpression may contribute to the development of NSCLCs by promoting proliferation and provide evidence that this role is further enhanced in a genetic background with deregulated pRb–p53–MDM2 circuitry. Copyright © 2002 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626 · cited 1×
“The absence of correlation with apoptosis in our series and the in vitro reports, which implicate E2F1 in inducing the apoptotic process [24,28,64–66], prompted us to investigate its relationship with the status of p53 protein, the main E2F-1 mediator of programmed cell death [15,67,68], and MDM2 protein, the principa…”
BackgroundPomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“The absence of correlation with apoptosis in our series and the in vitro reports, which implicate E2F1 in inducing the apoptotic process [24,28,64–66], prompted us to investigate its relationship with the status of p53 protein, the main E2F-1 mediator of programmed cell death [15,67,68], and MDM2 protein, the principa…”
BackgroundThe Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · cited 2×
“In vitro studies have indicated that E2F-1 could function either as an oncogene or as a tumour suppressor gene [1,2,7,17,18].”
Backgroundp14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918 · cited 2×
“myb, myc), (v) E2F-1 and E2F-2 transcription [1,2,7,14] and (vi) p53 stabilization by inducing the expression of p14ARF [15].”
Backgroundp53-Dependent apoptosis suppresses tumor growth and progression in vivo
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., & Van Dyke, T. (1994) · Cell · doi:10.1016/0092-8674(94)90534-7 · Cited by 880 · cited 2×
“This effect causes a survival pressure for the cell to eliminate, directly (via p53 mutations) and/or indirectly (MDM2 overexpression), the p53-dependent apoptotic response [78], while defective p53-independent apoptotic mechanisms can also cooperate [74].”
Background
Cited by
Emerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
The E2F transcriptional network: old acquaintances with new faces
Dimova, D. K., & Dyson, N. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208612 · Cited by 715
“Numerous groups have found deregulated E2F activity in different human cancers, often correlating with poor prognosis (see for examples Nevins, 2001; Gorgoulis et al., 2002; Ebihara et al., 2004; Foster et al., 2004).”
BackgroundRayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Involvement of E2F transcription factor family in cancer
Tsantoulis, P. K., & Gorgoulis, V. G. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.005 · Cited by 163
“It is noteworthy that, with the exception of the trinucleotide repeat region in E2F4, the E2F family is generally not a common target for mutations in cancer as we [131] and others [165] have noticed (also reviewed in [166]).”
BackgroundInfluentialSelf-citationIntegrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
“Hence, inactivation of p16INK4A –Rb signalling is not a surprising finding in cancer [221,334–337], as it releases E2F transcription factor 1 (E2F1) from its inhibitory control [329,333,338,339], stimulating the sustained expression of cell-cycle drivers such as cyclin E, Cdc6, and Cdt1, converting them into ‘oncogeni…”
BackgroundSelf-citation
Metadata
- Authors
- Gorgoulis, V. G., Zacharatos, P., Mariatos, G., Kotsinas, A., Bouda, M., Kletsas, D., Asimacopoulos, P. J., Agnantis, N., Kittas, C., & Papavassiliou, A. G.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2002-09-17
- Volume
- 198
- Issue
- 2
- Pages
- 142-156
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2090258042
- Cited by
- 153
- References
- 6
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.